Novavax Other Current Assets

The latest other current assets for NVAX is $23M as of June 2026. That compares with $60M in the prior-year period — down 61.5% year over year. Investors often review this figure alongside Novavax's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVAX's other current assets moved from $60M to $23M — a 61.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novavax's operating scale or balance-sheet position.

A other current assets figure of $23M for NVAX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NVAX's other current assets ($23M), review year-over-year change from $60M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Novavax's other current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.